drugset / Trial / NCT03475342

World Maternal Antifibrinolytic Trial_2

NCT03475342

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.

Timeline

Start
2019-08-24
Primary completion
2023-09-20
Completion
2023-10-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 1 g Intravenous

Indications

No indication recorded.